Skip to main content
. 2021 Jul 22;15(12):3430–3446. doi: 10.1002/1878-0261.13052

Fig. 3.

Fig. 3

CPT1A might be a promising target to reverse oxaliplatin resistance in colon cancer. (A) Differential expression of CPT1A was identified by IHC staining in human colon cancer tissues and paired normal tissues (n = 13). (B) Western blotting analysis of CPT1A expression in different colon cancer cell lines and grey value analysis of CPT1A protein (n = 3, mean ± SEM, t‐test). (C–D) Expression of CPT1A after oxaliplatin stimulation by western blotting (C) and qRT‐PCR (D); all Y‐axes indicate the fold change of CPT1A (n = 3, mean ± SEM, t‐test). (E–F)Verification of CPT1A expression after siRNA transfection by western blotting (E) and qRT‐PCR (F), all y‐axes indicate the fold change of CPT1A (n = 3, mean ± SEM, t‐test). *P < 0.05; **P < 0.01; ***P < 0.001.